asa statement on glp 1 GLP-1 and Anesthesia: Considerations and Cautions for CRNAs ASA Advises No Longer Holding

Received: 11 Jun 2025 | Revised: 29 Jul 2025 | Accepted: 31 Jul 2025 | Published: 27 Jan 2026 1

The primary endpoint, and, unless indicated otherwise, all continuous secondary endpoints were analyzed for a treatment effect (dulaglutide versus placebo) using linear mixed-effect models (LMMs)

Sequencing of pharmaceutical therapeutics With 4 drug classes showing evidence of kidney and cardiovascular benefit for people with CKD, the challenge becomes which order to start these therapies

Implications for employers: GLP-1 medications can cause GI problems and that is why starting doses are gradually increased

Investigations of thyroid hormones and antibodies in obesity: leptin levels are associated with thyroid autoimmunity independent of bioanthropometric, hormonal, and weight-related determinants

Bo Hjorth Bentzen, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3, 2200 Copenhagen N, Denmark